JH Vallance
Ninewells Hospital, Dundee, UK E-mail: jamesvallance@nhs.net We thank Dr Vallance 1 for his interest in our recent review. To begin with, it is of the utmost importance to point out that Dr Vallance did not actually voice any objections or doubts concerning the scientific facts and the information given in our comprehensive review comparing the aspects of ranibizumab and bevacizumab in relation to their molecular characteristics, in vitro and in vivo properties, and preclinical safety data. 2 The issue in question here is Dr Vallance objection to the fact that a medical writer funded by Novartis helped with the preparation of the manuscript. Dr Vallance even goes so far as to insinuate that the authors did not write the article at all. He bases his speculations on the fact that the company Mr Cunningham (the medical writer) works for also supplies 'complete medical communication services for all marketing needs'. With his reference to an article in 'The Guardian' 3 Dr Vallance finally draws comparison between the review article and ghostwriting commissioned by Wyeth, resulting in scientific articles of questionable content.
To us these allegations and insinuations are libellous. First, we have written our review in accordance with the guidelines of the International Committee of Medical Journal Editors (ICMJE). The Committee defines the criteria for authorship as follows:
Authors should have participated sufficiently in the work to take public responsibility for relevant portions of the content and should meet all three conditions below: Substantial contribution to conception and design, acquisition of data, or analysis and interpretation of data; and drafting the article or revising it critically for important intellectual content; and final approval of the version to be published. 4 Second, professional medical writers are not ghostwriters. The Association of American Medical Colleges states: 'Transparent writing collaboration with contribution between academic and industry investigators, medical writers and/or technical experts is not ghostwriting. It is recommended that particular care is taken to ensure appropriate acknowledgment of the contribution made by medical writers and to describe their funding. If such assistance was available, the authors should disclose the identity of the individuals who provided this assistance and the entity that supported it in the publishing article. Companies funding the work of medical writers should ensure that writers follow good publication practice'. 4 Finally, the guidelines to the publication policies of Nature Journals including Eye require a statement of responsibility in the manuscript that specifies the contribution of each author (http://www.nature.com/ authors/gta.pdf). According to the journal an exemplary definition of abuse of financial interest are academic authors who have been paid by pharmaceutical companies to put their names and credibility to reviews produced by ghostwriters employed to boost company products. On the other hand, the journal explicitly states that the financial interests do not invalidate research studies or review articles at all. Authors should identify individuals who provided writing or other assistance and disclose the funding source for this assistance.
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In our review article we clearly state the name of the medical writer, name his company as well as the funding
Sir, Response to Vallance
In response to Dr Vallance's letter, 1 we refute the implication that this article 2 is an example of 'medical ghostwriting'. Alpha-Plus Medical Communications acts in accordance with good publication practice guidelines (GPP2) as published in the BMJ, 3 and confirms that there was no exception with this article. The authors provided direction, had full control of the editorial content, and accepted full responsibility for views and opinions as well as accuracy of the content. 4 A clear and unambiguous statement regarding our involvement in this publication was included in the acknowledgements.
In relation to Dr Vallance's claim that Alpha-Plus provides 'complete medical communication services for all marketing needs', we would like to highlight that the source of this statement is an out-of-date and obsolete business listing from early 2009. We thank Dr Vallance for drawing our attention to this listing and have requested that it is removed at the earliest opportunity. Please refer your reader to our website (http:// www.fishawack.com) for up-to-date and accurate information regarding our group of companies. As you will note on our website, publication activities are separate from other medical communications services.
We would like to add that with regard to comments made about the appointment of Jo Jarvis, the conference in which Jo participated focused on how the industry should interact with different stakeholder groups (including physicians) in an ethically responsible manner and in compliance with the latest code of practice governing this area. We report a case of central serous chorioretinopathy (CSCR) following oral tadalafil (Cialis, Lilly-ICOS LLC) use. A review of the literature found one post-marketing surveillance study in which patients with CSCR showed no increase in prescription exposure to phosphodiesterase type 5 (PDE-5) enzyme inhibitors compared with their age-matched controls. 1 Case report A 51-year-old man with no significant past medical history presented with painless reduced central vision in the left eye of 2 weeks duration. His vision became
